Dosing protocol8 min
The retatrutide titration ladder, explained.
The 0.25 → 12 mg ladder we publish on every COA — what each step is doing, why side effects cluster at week 4, and when to hold.
— Recent · last 30 days
Latest publications.
147 articles total. Filter by category above. Every piece is byline-credited and CSO-reviewed before publish.
Long read
N° 147
Mechanism explainer14 min
The full mechanism of triple-agonist GLP-1.
Retatrutide engages three receptors at once. The interactions matter — here's what the pharmacology actually says.
M
Dr. Maya CastellanosApr 28Protocol
N° 146
Dosing protocol8 min
The retatrutide titration ladder.
Why we publish 0.25→12 mg — and not the 1.0 mg start that some clinics push. What's happening at each step.
M
Dr. Maya CastellanosApr 22Study digest
N° 145
Study summary11 min
EMERALD-2 · what 24.2% really means.
A careful read of the Phase 2 retatrutide trial: outcomes, dropouts, and what the press release left out.
A
Dr. Aiyana ReevesApr 15Safety
N° 144
Safety & interactions7 min
When not to stack BPC-157 with TB-500.
The pairing is popular and mostly fine. But three contraindications come up often enough to be worth naming explicitly.
N
Dr. Naveen PatelApr 11Lab method
N° 143
Methods & lab9 min
Why our purity floor is 99.0% — not 98%.
One percentage point on a label isn't marketing — it's an order-of-magnitude difference in residual impurity load. Here's the math.
M
Dr. Maya CastellanosApr 06Field report
N° 142
Field report12 min
Eight patients, twelve weeks, 4 mg reta.
Real protocols, real logs, real side-effect timelines. We pulled their writeups, scrubbed identifiers, and asked: what holds across the cohort?
J
Dr. James HollowayMar 30Long read
N° 141
Mechanism explainer10 min
What GIP does — and doesn't — do for body composition.
The GIP receptor was the surprise. We walk through what it adds to the GLP-1 picture, and where the data are still messy.
A
Dr. Aiyana ReevesMar 24Protocol
N° 140
Dosing protocol6 min
Pulsing Ipamorelin + CJC-1295.
Why pulsed dosing matters more here than for any other peptide we sell. Three patterns patients actually use.
N
Dr. Naveen PatelMar 19Study digest
N° 139
Study summary13 min
SURMOUNT-1 vs STEP-5 — the cross-comparison.
Tirzepatide and semaglutide ran their flagship Phase 3s under similar conditions. We pulled the matched outcomes side-by-side.
A
Dr. Aiyana ReevesMar 14— Study digest · Week 17, 2026
The papers we read this week.
A standing column. Every Monday our research team reads the new pre-prints and Phase 1/2/3 readouts in our space, summarizes them, and rates how much weight to put on each one. Verdicts: holds — replicates and methods are sound; mixed — interesting but watch the confounds; weak — don't change protocol on this yet.
D-2604-08
Long-term retatrutide effects on hepatic fat fraction.
Lancet Diabetes & Endocrinology · n=348 · 48 wk−42% liver-fat fraction at 48 weeks vs −18% with semaglutide-equivalent. Powered, MRI-PDFF measured.
Holds D-2604-07BPC-157 + low-dose doxycycline in tendon repair.
J Sports Med · n=42 · 12 wk · single-blindFunctional benefit clear; combo arm vs BPC-only didn't separate. Doxy was probably noise.
Mixed D-2604-06Tirzepatide and cardiovascular outcomes: SURPASS-CVOT pre-print.
Pre-print · MedRxiv · n=13,299 · 5 yr17% relative MACE reduction vs glargine. Pre-print but methodology checks out.
Holds D-2604-05Epitalon and telomere length in aged peripheral lymphocytes.
Aging · n=30 · 12 wkEffect direction OK but n is small, blinding fragile, and the assay vendor changed mid-study. Don't move on this.
Weak D-2604-04GHK-Cu topical, full-thickness wound closure rate, RCT.
Wound Repair Regen · n=88 · 8 wkClosure-rate hazard ratio 1.34 (CI 1.08–1.66). Replicates earlier work — comfortable signal.
Holds— Standing series
Five running columns.
Series we publish on a schedule. New entries land on a fixed cadence — our patients know when to look for them, and the index keeps every episode threaded.
Mondays · study digest.
Every Monday, three to five new papers in our space, summarized, rated, and indexed. 47 issues archived.
47 issues→
The field report.
De-identified protocol logs from our verified-customer cohort, aggregated into one readout per quarter. 14 reports archived.
14 reports→
Lab notes from the bench.
What our chemists ran into this month — failed lots, weird HPLC traces, equipment service stories. The unvarnished version.
22 entries→
The protocol library.
Titration, pulsing, taper, layering — one canonical protocol per peptide, updated as evidence drifts. 14 protocols, all signed.
14 protocols→
Compare-table deep-dives.
One article per molecule pair, going through the comparison row-by-row instead of letting the table speak alone.
9 deep-dives→
Live-pulse signal log.
What our verified-researcher community is reporting in real time — wired to our protocol-thread system. Updated hourly.
Live→
— The Element MD dispatch
Get the Monday digest.
One email each Monday: the studies we read, the protocols we updated, the lots we released. 9-minute read average. No marketing, no upsells, unsubscribe in one click.
Joining 8,420 patients · we send Mondays at 7am ET
8.4k
Subscribers
47k
Issues sent
62%
Open rate
0k
Sponsored items